Almirall delivered net sales growth of 12.4% in 2025, surpassing €1 billion, driven by strong European dermatology performance and continued progress across its biologics portfolio.

The company reported total revenue of €1,114.5 million, with EBITDA rising 20.9% to €232.9 million, reflecting both operational efficiency and sustained investment in R&D. Growth was led by the European dermatology business, which increased 25.6% year-on-year to €608 million, highlighting the relevance of its advanced products in psoriasis and atopic dermatitis.

Key biologics contributed significantly to Almirall’s growth. Ilumetri net sales increased 12.3% to €234.4 million, while Ebglyss more than tripled year-on-year to €110.8 million, reflecting its strong uptake across European markets. The broader dermatology portfolio also performed well, with Wynzora growing 30.5% to €33.8 million and Klisyri up 33.9% to €32.8 million.

Carlos Gallardo, chairman and CEO, said the figures demonstrate both growth and strategic execution: “2025 was another important year for Almirall as we continue to deliver against our sustained growth trajectory and further expand our leadership in medical dermatology. Another year of double-digit growth of both net sales at 12.4% and EBITDA at 21.0%, demonstrates Almirall’s strong business performance and focus on executional excellence. Our broad portfolio of dermatology products is the driver of our increasing relevance to patients and the medical community with our advanced biologics Ilumetri and Ebglyss leading our overall growth.”

He added that continued business strength enables ongoing investment in the pipeline, noting around 12.5% of sales were allocated to R&D in 2025, supporting studies including the Phase 2 anti-IL-1RAP monoclonal antibody in hidradenitis suppurativa, and the IL-2muFc in alopecia areata. Regulatory approvals during the year included Jublia in Germany and Seysara in China, while additional Phase 2 and proof-of-concept studies are expected in 2026.

Fabio Cataldi, chief medical officer, emphasised the portfolio’s patient impact: the combination of established and pipeline products positions Almirall to address multiple dermatological conditions and unmet needs, from psoriasis to atopic dermatitis, and provides physicians with a broader range of treatment options.

Looking ahead, Almirall expects net sales growth of 9%-12% in 2026 with total EBITDA projected between €270 million and €290 million, reflecting both ongoing commercial execution and continued investment in research and development.